Alpha Tau Medical

DRTS

Market cap $607M

- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treatments, as well as potential anti-inflammatory effect - - Alpha DaRT currently being studied together with first-line chemotherapy in U.S. multi-center pilot trial for newly diagnosed pancreatic cancer - JERUSALEM, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced the release of final results from its first-in-human pancreatic cancer study in Montreal, Canada exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma (PDAC).

- Initial module submission marks an important milestone in the pre-market approval process -  - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted - - Module submitted in parallel to execution of ReSTART pivotal study ( Re current S CC T reatment with A lpha DaRT R adiation T herapy), which is expected to complete recruiting patients in Q1 2026 - JERUSALEM, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced the submission of the first module of its pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA), following the FDA's previous decision to allow the Company to use the more flexible modular approach.

- First patient in the world treated with Alpha DaRT ® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months – - This pilot study is a key part of Alpha Tau's broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs - JERUSALEM, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that the first patient has been treated in its pilot study for the treatment of patients with recurrent glioblastoma multiforme (GBM) using the Alpha DaRT technology.

-  Alpha DaRT pancreatic cancer p atient treatments underway in U.S. multi-center pilot study -

JERUSALEM, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate at the Jefferies Global Healthcare Conference in London on November 18-19, 2025.

-  Receipt of c ritical license marks significant milestone for f irst commercial-scale manufacturing facility for Alpha DaRT ®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation -

Alpha DaRT, a unique localized alpha radiation therapy, has shown potential best-in-class efficacy and safety across multiple solid tumors. Currently enrolling patients in cSCC, HNSCC, pancreatic, and GBM (before year end), with a number of milestones across each indication over the next 12-18 months. Despite promising early data and broad potential, Alpha Tau's is currently significantly undervalued at ~$330 million market cap, especially in light of recent acquisitions and trading activity.

– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program –

JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present and meet investors in the following five investor conferences in September 2025.

- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer -